Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS)

Kyeongman Jeon, Jae-Uk Song, Chi Ryang Chung, Jeong Hoon Yang, Gee Young Suh, Kyeongman Jeon, Jae-Uk Song, Chi Ryang Chung, Jeong Hoon Yang, Gee Young Suh

Abstract

Background: Vasopressin (AVP) is commonly added to norepinephrine (NE) to reverse shock in patients with sepsis. However, there are no data to support the appropriate strategy of vasopressor tapering in patients on concomitant NE and AVP who are recovering from septic shock. Therefore, the objective of this study was to evaluate the incidence of hypotension while tapering vasopressors in patients on concomitant NE and AVP recovering from septic shock.

Methods: Patients with septic shock receiving concomitant NE and AVP were randomly assigned to taper NE first (NE group) or AVP first (AVP group). The primary end point was the incidence of hypotension within one hour of tapering of the first vasopressor. We also evaluated the association between serum copeptin levels and the occurrence of hypotension.

Results: The study was stopped early due to a significant difference in the incidence of hypotension after 38 and 40 patients were enrolled in the NE group and the AVP group, respectively. There were 26 patients (68.4%) in the NE group versus 9 patients (22.5%) in the AVP group who developed hypotension after tapering the first vasopressor (p < 0.001). There was a similar finding during the subsequent tapering of the second vasopressor (64.5% in the NE vs 25.0% in the AVP group, p = 0.020). Finally, NE tapering was significantly associated with hypotension during the study period (hazard ratio, 2.221; 95% confidence interval, 1.106-4.460; p = 0.025). The serum copeptin level was lower in patients in whom hypotension developed during tapering of AVP than it was in those without hypotension.

Conclusions: Tapering NE rather than AVP may be associated with a higher incidence of hypotension in patients recovering from septic shock who are on concomitant NE and AVP. However, further studies with larger sample sizes are required to better determine the appropriate strategy for vasopressor tapering.

Trial registration: ClinicalTrials.gov, NCT01493102 . Registered on 15 December 2011.

Keywords: Hypotension; Norepinephrine; Septic shock; Treatment outcome; Vasopressin.

Conflict of interest statement

Ethics approval and consent to participate

The institutional review board of the Samsung Medical Center approved this study and informed consent was obtained from each patient or the patient’s relative or surrogate.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study protocol on titrating vasopressors. NE, norepinephrine; MAP, mean arterial pressure; AVP, vasopressin
Fig. 2
Fig. 2
Flow chart of the screening and randomization process
Fig. 3
Fig. 3
Comparisons of serum copeptin levels between patients with and without hypotension after the first vasopressor was tapered (a-c) and after sequential tapering all infused vasopressors (d-f). Data are expressed as medians (interquartile ranges). AVP, vasopressin; NE, norepinephrine

References

    1. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005;365:63–78. doi: 10.1016/S0140-6736(04)17667-8.
    1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–377. doi: 10.1007/s00134-017-4683-6.
    1. Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med. 2011;183:847–855. doi: 10.1164/rccm.201006-0972CI.
    1. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ, Investigators V. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316:509–518. doi: 10.1001/jama.2016.10485.
    1. Vail EA, Gershengorn HB, Hua M, Walkey AJ, Wunsch H. Epidemiology of vasopressin use for adults with septic shock. Ann Am Thorac Soc. 2016;13:1760–1767.
    1. Merouani M, Guignard B, Vincent F, Borron SW, Karoubi P, Fosse JP, Cohen Y, Clec'h C, Vicaut E, Marbeuf-Gueye C, Lapostolle F, Adnet F. Norepinephrine weaning in septic shock patients by closed loop control based on fuzzy logic. Crit Care. 2008;12:R155. doi: 10.1186/cc7149.
    1. Persichini R, Silva S, Teboul JL, Jozwiak M, Chemla D, Richard C, Monnet X. Effects of norepinephrine on mean systemic pressure and venous return in human septic shock. Crit Care Med. 2012;40:3146–3153. doi: 10.1097/CCM.0b013e318260c6c3.
    1. Guinot PG, Bernard E, Levrard M, Dupont H, Lorne E. Dynamic arterial elastance predicts mean arterial pressure decrease associated with decreasing norepinephrine dosage in septic shock. Crit Care. 2015;19:14. doi: 10.1186/s13054-014-0732-5.
    1. Bauer SR, Aloi JJ, Ahrens CL, Yeh JY, Culver DA, Reddy AJ. Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: a retrospective cohort study. J Crit Care. 2010;25:362 e367–362 e311. doi: 10.1016/j.jcrc.2009.10.005.
    1. Landry DW, Levin HR, Gallant EM, Ashton RC, Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122–1125. doi: 10.1161/01.CIR.95.5.1122.
    1. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA., 3rd Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med. 2001;29:487–493. doi: 10.1097/00003246-200103000-00004.
    1. Rachoin JS, Dellinger RP. Timing of norepinephrine in septic patients: NOT too little too late. Crit Care. 2014;18:691. doi: 10.1186/s13054-014-0691-x.
    1. Hammond DA, McCain K, Painter JT, Clem OA, Cullen J, Brotherton AL, Chopra D, Meena N. Discontinuation of vasopressin before norepinephrine in the recovery phase of septic shock. J Intensive Care Med. 2017:885066617714209. 10.1177/0885066617714209. [Epub ahead of print].
    1. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, Surviving Sepsis Campaign Management Guidelines C Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–873. doi: 10.1097/01.CCM.0000117317.18092.E4.
    1. Jeon K, Shin TG, Sim MS, Suh GY, Lim SY, Song HG, Jo IJ. Improvements in compliance with resuscitation bundles and achievement of end points after an educational program on the management of severe sepsis and septic shock. Shock. 2012;37:463–467. doi: 10.1097/SHK.0b013e31824c31d1.
    1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative G Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307.
    1. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaud P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862–871. doi: 10.1001/jama.288.7.862.
    1. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973;52:2340–2352. doi: 10.1172/JCI107423.
    1. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112–119. doi: 10.1373/clinchem.2005.060038.
    1. Jochberger S, Luckner G, Mayr VD, Wenzel V, Morgenthaler NG, Friesenecker BE, Hasibeder WR, Dunser MW. Course of vasopressin and copeptin plasma concentrations in a patient with severe septic shock. Anaesth Intensive Care. 2006;34:498–500. doi: 10.1177/0310057X0603400415.
    1. Lan KG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659–663. doi: 10.2307/2336502.
    1. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med. 2003;31:1752–1758. doi: 10.1097/01.CCM.0000063046.82359.4A.
    1. Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Friesenecker B, Mayr AJ, Dunser MW. Serum vasopressin concentrations in critically ill patients. Crit Care Med. 2006;34:293–299. doi: 10.1097/01.CCM.0000198528.56397.4F.
    1. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med. 2003;31:2646–2650. doi: 10.1097/01.CCM.0000094260.05266.F4.
    1. Russell JA, Walley KR, Gordon AC, Cooper DJ, Hebert PC, Singer J, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Dieter Ayers for the V, Septic Shock Trial I Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med. 2009;37:811–818. doi: 10.1097/CCM.0b013e3181961ace.
    1. Gordon AC, Mason AJ, Perkins GD, Stotz M, Terblanche M, Ashby D, Brett SJ. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med. 2014;42:1325–1333. doi: 10.1097/CCM.0000000000000212.
    1. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588–595. doi: 10.1056/NEJMra002709.
    1. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med. 2004;30:1276–1291.
    1. Palmiere C, Augsburger M. Copeptin as a diagnostic biomarker for sepsis-related deaths. Peptides. 2014;59:75–78. doi: 10.1016/j.peptides.2014.07.011.
    1. Jochberger S, Dorler J, Luckner G, Mayr VD, Wenzel V, Ulmer H, Morgenthaler NG, Hasibeder WR, Dunser MW. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med. 2009;37:476–482. doi: 10.1097/CCM.0b013e3181957532.
    1. Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med. 2009;37:3114–3119. doi: 10.1097/CCM.0b013e3181bc7bd5.
    1. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989–1002. doi: 10.1378/chest.120.3.989.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner